title: Novartis' lung cancer ALK inhibitor approved.
authors.forename: Malini
authors.initials: M
authors.lastname: Guha
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D013450:Sulfones / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D011743:Pyrimidines; D013450:Sulfones; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; C586847:ceritinib